Naloxone intranasal - Amphastar

Drug Profile

Naloxone intranasal - Amphastar

Latest Information Update: 28 Feb 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Amphastar Pharmaceuticals
  • Class Antidotes; Morphinans; Small molecules
  • Mechanism of Action Opioid receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preregistration Opioid abuse

Most Recent Events

  • 21 Feb 2017 Amphastar Pharmaceuticals receives complete response letter from the FDA for Naloxone intranasal in Opioid abuse
  • 19 May 2016 Chemical structure information added
  • 01 Apr 2016 Preregistration for Opioid abuse in USA (Intranasal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top